Novanta Inc. (NOVT) Q3 Revenue Rose 23.1% to $305M; 2026 Revenue Outlook $1.135B–$1.140B

Novanta Inc. reported Q3 2026 revenue of $305M, up 23.1% YoY, and adjusted EPS of $1.05, up 20.7%. The company expects 2026 revenue of $1.135B–$1.140B, indicating ~16% growth. Next catalysts include Q4 execution and progress toward full-year targets.

Original reporting

tradingview.com

Published Nov 9, 2026, 9:45 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 9, 2026, 9:52 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Novanta Inc. (NOVT) Q3 Revenue Rose 23.1% to $305M; 2026 Revenue Outlook $1.135B–$1.140B — source image — Source · tradingview.com

Decision brief

The 30-second read

$NOVTBullishMed

Why it matters

The earnings beat and raised outlook provide a fresh catalyst for the stock, likely prompting short‑term buying.

Market read

First‑report earnings and guidance for a small‑cap med‑tech firm, offering actionable insight for traders.

What to watch

Potential supply‑chain constraints or slower adoption of new products could temper growth.

Relevance 8/10Novelty 8/10Timing: post‑market release

Background

Novanta Inc. released its Q3 2026 earnings, highlighting organic growth and acquisition‑driven expansion.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$NOVTBullishHigh confidence

Context

Q3 2026 revenue rose 23.1% to $305M and 2026 outlook raised to $1.135B‑$1.140B.

Expected impact

likely upward pressure as market prices in higher revenue outlook

Evidence & confidence

Revenue beat and raised full‑year guidance are fresh, material data that can move the share price.

Market effects

Sector

Strong growth in medical‑technology equipment may lift peers in the med‑tech sector.

Regional

U.S. small‑cap biotech/medical device space could see modest buying interest.

Global

Limited to investors focused on U.S. listed med‑tech companies.

Counterpoint

What could challenge this read

If the guidance is already priced in, the stock may face disappointment on execution risk.

Key entities

Company
Novanta Inc.
U.S. medical‑technology equipment provider (ticker NOVT).

Read at source ← All news

$NOVTHighAI 8/10

Why is Novanta stock tumbling today?

Novanta (NOVT) shares fell 14.7% after Q3 2026 earnings call, with GAAP operating margin dropping to 4.6% from 11.5% YoY. Adjusted EPS guidance for Q4 was reduced to $0.91–$0.96, below consensus of $1.02. Insider selling and macroeconomic concerns added to the decline, with shares hitting an intraday low of $120.24.

investing.comNov 10

$NOVTHighAI 8/10

Novanta’s (NASDAQ:NOVT) Q3 2026 sales beat estimates but guides down full-year adjusted EPS

Novanta reported Q3 2026 sales of $305M, beating estimates by 1.3%. Adjusted EPS was $1.05, an 8.6% beat. Adjusted EBITDA was $80.34M, a 4.4% beat. Q4 revenue guidance is $309M, in line with estimates. Full-year adjusted EPS guidance was lowered to $3.69. Operating margin declined to 4.6% from 11.5% YoY, while free cash flow margin increased to 10% from 1.7%.

finance.yahoo.comNov 9

$NOVTMedAI 8/10

Novanta earnings beat by $0.11, revenue topped estimates

Novanta (NOVT) reported Q3 EPS of $1.05, beating estimates by $0.11, with revenue at $305M, surpassing expectations of $262.82M. The company provided Q4 and FY 2026 guidance, with EPS and revenue estimates generally in line with or slightly below consensus. NOVT's stock is down 12.72% over the last 3 months but up 40.37% year-over-year.

investing.comNov 9

$NOVTMed

Novanta 3Q 2026: Revenue $305.01M, EPS $0.05 — 10-Q Summary

Novanta reported 3Q 2026 revenue of $305.01M, up 23.1% YoY, but net income fell 81.1% to $2.02M due to higher costs. Automation segment revenue rose 16%, while Medical Solutions grew 30.3%, including $32.9M from Riverpoint Medical acquisition. Gross margins varied across segments.

tradingview.comNov 9

$NOVTHigh

Novanta: Q3 Earnings Snapshot

Novanta Inc. (NOVT) reported Q3 net income of $2M, or 5 cents per share, with adjusted earnings of $1.05 per share. Revenue was $305M. For Q4, it forecasts earnings of 91-96 cents per share and revenue of $306M-$312M. Full-year earnings are expected to be $3.66-$3.71 per share, with revenue of $1.14B.